289 related articles for article (PubMed ID: 26402059)
1. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Citrome L; Stensbøl TB; Maeda K
Expert Rev Neurother; 2015 Oct; 15(10):1219-29. PubMed ID: 26402059
[TBL] [Abstract][Full Text] [Related]
2. Brexpiprazole: First Global Approval.
Greig SL
Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
[TBL] [Abstract][Full Text] [Related]
3. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
4. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
5. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Citrome L
Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
[TBL] [Abstract][Full Text] [Related]
6. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of brexpiprazole: comparison with aripiprazole.
Stahl SM
CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
[TBL] [Abstract][Full Text] [Related]
9. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Hope J; Castle D; Keks NA
Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.
McKeage K
CNS Drugs; 2016 Feb; 30(2):91-9. PubMed ID: 26849053
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization.
Oosterhof CA; El Mansari M; Blier P
J Pharmacol Exp Ther; 2014 Dec; 351(3):585-95. PubMed ID: 25225185
[TBL] [Abstract][Full Text] [Related]
12. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.
Yoshimi N; Fujita Y; Ohgi Y; Futamura T; Kikuchi T; Hashimoto K
Pharmacol Biochem Behav; 2014 Sep; 124():245-9. PubMed ID: 24955861
[TBL] [Abstract][Full Text] [Related]
13. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator.
Maeda K; Lerdrup L; Sugino H; Akazawa H; Amada N; McQuade RD; Stensbøl TB; Bundgaard C; Arnt J; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):605-14. PubMed ID: 24947464
[TBL] [Abstract][Full Text] [Related]
14. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Ishima T; Futamura T; Ohgi Y; Yoshimi N; Kikuchi T; Hashimoto K
Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole: another multipurpose antipsychotic drug?
Howland RH
J Psychosoc Nurs Ment Health Serv; 2015 Apr; 53(4):23-5. PubMed ID: 25856810
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
[TBL] [Abstract][Full Text] [Related]
17. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
Ekinci A; Ekinci O
Rev Recent Clin Trials; 2018 Jan; 13(1):37-44. PubMed ID: 28828976
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole for the treatment of schizophrenia.
Hsu WY; Lane HY; Lin CH
Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
[TBL] [Abstract][Full Text] [Related]
19. Brexpiprazole: A Review in Schizophrenia.
Frampton JE
Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
[TBL] [Abstract][Full Text] [Related]
20. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
Stummer L; Markovic M; Maroney M
Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
